| Přispěvatelé: |
Broccoli, Alessandro, Argnani, Lisa, Coppola, Paolo Elia, Gentilini, Marianna, Bagnato, Gianmarco, Lolli, Ginevra, Carella, Matteo, Nanni, Laura, Morigi, Alice, Casadei, Beatrice, Pellegrini, Cinzia, Stefoni, Vittorio, Zinzani, Pier Luigi |
| Popis: |
The follow-up of the pivotal trial and large case series reports of a proportion of patients, between 5% and 9%, with relapsed or refractory Hodgkin lymphoma failing autologous stem cell transplantation and treated with brentuximab vedotin, achieving and maintaining long lasting complete responses with no further treatment. Very long-term data on the outcomes of such patients are indeed underreported. Our institutional experience with patients meeting these characteristics and in continuous complete response for more than 5 years after brentuximab vedotin was reviewed. Five patients achieved a median duration of complete response of 7.4 (range 5.1-8.1) years, and none of them encountered disease relapse or received any subsequent consolidation, including allogeneic transplantation. A proportion of patients failing autologous transplantation and receiving subsequent brentuximab vedotin may reach a long-lasting complete response with no need of further treatment. These patients are therefore considered cured. The role of allogeneic transplantation in such patients is matter of debate. |
